Benefit of glinides is not proven

The benefit of glinides in the treatment of type 2 diabetes is not scientifically proven. Nor do they perform better than other antidiabetics available in tablet form, such as metformin and sulfonylureas. As a result, there is also no proof of additional benefit. Although repaglinide has been approved for 10 years and nateglinide for 8 years in Germany, there have been no relevant trials to date of longer duration than 14 months. This is the conclusion of a report by the German Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, which was published in June 2009 and for which an English-language summary is now available.

Therapy option for patients with...

Want to see the full article?

• Purchase this article for only $3.00